Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia

NCT05073458 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT05073458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05073458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia
Lead sponsor
Incyte Corporation
Phase
Phase 3
Overall status
Terminated
Start date
March 15, 2022
Completion date
April 29, 2024
Enrollment
13 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

warm autoimmune hemolytic anemia (waiha)